Evidence map›Paper›PMID 29962065›Full record

ArticleCPT: pharmacometrics & systems pharmacology2018

Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating Oxygenation.

Sina Saffaran, Wenfei Wang, Anup Das, Walter Schmitt, Eva-Maria Becker-Pelster, Jonathan G Hardman, Gerrit Weimann, Declan G Bates

Open access · goldAbstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Sina SaffaranSchool of Engineering, University of Warwick, Coventry, West Midlands, UK.
Wenfei WangSchool of Engineering, University of Warwick, Coventry, West Midlands, UK.
Anup DasSchool of Engineering, University of Warwick, Coventry, West Midlands, UK.
Walter SchmittClinical Science, Bayer Healthcare, Barmen, Germany.
Eva-Maria Becker-PelsterClinical Science, Bayer Healthcare, Barmen, Germany.
Jonathan G HardmanSchool of Medicine, University of Nottingham, Nottingham, UK.
Gerrit WeimannClinical Science, Bayer Healthcare, Barmen, Germany.
Declan G BatesSchool of Engineering, University of Warwick, Coventry, West Midlands, UK.
University of Warwick · GBBayer (United States) · USBayer (Germany) · DEUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study uses a highly fidelity computational simulator of pulmonary physiology to evaluate the impact of a soluble guanylate cyclase (sGC) modulator on gas exchange in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH) as a complication. Three virtual patients with COPD were configured in the simulator based on clinical data. In agreement with previous clinical studies, modeling systemic application of an sGC modulator results in reduced partial pressure of oxygen (PaO

Indexed as

Hydrogen-Ion ConcentrationAdministration, InhalationEnzyme InhibitorsHumansOxygenPulmonary Disease, Chronic ObstructiveSoluble Guanylyl CyclaseEnzyme InhibitorsOxygenSoluble Guanylyl Cyclase

Identifiers

PMID29962065
PMCPMC6118299
OpenAlexW2809755908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.